IOR-160 

IOR-160 is a dual inhibitor of casein kinase 2 (CK2) and HDACs. IOR-160 exhibits high selectivity for CK2 (IC₅₀ = 1.7 nM) and broad inhibitory activity against HDAC (HDAC 1, 2, 3, and 6 with IC₅₀s of 3.3 nM, 24.0 nM, 3.9 nM, and 13.0 nM, respectively, with low activity for HDAC8). IOR-160 modulates key cellular signaling pathways by inhibiting AKT phosphorylation and increasing acetylated α-tubulin. IOR-160 inhibits tumor growth and reduces tumor burden through dual CK2/HDAC inhibition. IOR-160 is indicated for use in triple-negative breast cancer research^[1].

IOR-160 (0.5 μM) shows high inhibitory for CK2 and HIPK2, with remanent activities of -6 % and 7 %, while showing moderate to low inhibition of DYRK1A, CLK2, Pim-1, Mnk2, DRAK1, and TrkA (from 18% to 65%)^[1].
IOR-160 shows less potency for HDAC8, with an IC₅₀ of 2200 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IOR-160 (1.0 mg in 100 μL of PBS, injected intratumorally, three times a week, 26 days) reduces tumor growth through dual CK2/HDAC inhibition in nonobese diabetic (NOD) scid gamma mice bearing MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

510.46

C₂₃H₂₅F₃N₄O₆

2421119-78-8

O=C(NO)CCCCCCCNC1=NC2=C(C=CC(C(O)=O)=C2)C3=CN=CC=C31.O=C(O)C(F)(F)F

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ortín I, et al. Targeting Casein Kinase 2 and Histone Deacetylase with a Dual Inhibitor Effectively Reduces Tumor Growth in a Triple-Negative Breast Cancer Xenograft Model. ACS Pharmacol Transl Sci. 2025 Jul 1;8(7):2093-2105.  [Content Brief]